Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

Food and Healthcare Press Releases Tuesday July 9, 2019 11:00
BALI, Indonesia and SEOUL, South Korea--9 Jul--PRNewswire/InfoQuest

Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer in Korea, announced its participation in IMCAS Asia 2019 held in Bali, Indonesia July 5-7, 2019 to introduce the excellence of NABOTA(R) (Prabotulinumtoxin A).

The 13th year of IMCAS (International Master Course on Aging Science) Asia is one of the top international conferences for plastic surgery, dermatology and aesthetic science. This year, around 85 corporate participants and 2,200 physicians had the opportunity to participate in the event.

Daewoong hosted an exhibition booth and a stand-alone symposium to present the excellence of NABOTA and meaning of FDA approval as the first 900 kDa botulinum toxin after Botox. Dr. Hema Sundaram, a US dermatologist who participated in the global clinical trial and one of the faculty members of IMCAS Asia, had the opportunity to speak about a massive global study that involved over 2,100 subjects in the US, EU, and Canada.

Dr. Hema Sundaram said, "Every physician wants to treat their patients with a trustable drug product. Botulinum toxin drug product manufactured by Daewoong Pharmaceutical had successfully proved its excellent efficacy and safety through FDA approval based on the fact that its non-inferiority results to Botox in all aspects of wrinkle improvement and stability in large-scale global clinical trials."

Alongside the exhibition, the NABOTA Aesthetic Forum (NAF in Bali) was held by Daewoong Pharmaceutical to invite more than 30 dermatologists and aesthetic surgeons from 6 different countries. This forum was prepared by Daewoong Pharmaceutical for the 5thstraight year to share the opportunity to explore and update the new techniques and trends in the field.

With regards of first botulinum toxin clinical study in Vietnam, Dr. Pham Xuan Hung said, "In comparison study with NABOTA versus Botox, we have confirmed non-inferiority result to Botox, and it was an opportunity to confirm the excellent efficacy and safety of NABOTA from the Vietnamese as well."

"Throughout IMCAS Asia 2019, we have had a good opportunity to prove the excellence of NABOTA to global physicians. Based on NABOTA's proven excellence in quality and manufacturing process, we expect the significant increase of overseas sales and will continuously promote NABOTA's excellence and strengthen its position as a global brand," said Seongsoo Park, Executive Director of NABOTA Business Department in Daewoong Pharmaceutical.

Photo - https://photos.prnasia.com/prnh/20190709/2518038-1
Caption - Daewoong Pharmaceutical Co., Ltd in IMCAS Asia 2019

Latest Press Release

Biotech Conagen Acquires Production Platform of Therapeutic Proteins

Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The acquisition includes...

Pneuma Respiratory, Inc. Announces New Chairman of the Board

Pneuma Respiratory, Inc. announced that Board member Jay Morgan has assumed the position of Chairman of the Board. Pneuma's previous Chairman, Walt Robb, will remain a member of the Board of Directors. Jay Morgan served as VP Global Innovation and...

Global market of dietary supplement is welcoming a rising star GLYMATE

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product,...

Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent...

SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives. SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with...

Related Topics